Article
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Nature communications - 24 Aug 2021
Sun Hua, Cao Song, Mashl R Jay, Mo Chia-Kuei, Zaccaria Simone, Wendl Michael C, Davies Sherri R, Bailey Matthew H, Primeau Tina M, Hoog Jeremy, Mudd Jacqueline L, Dean Dennis A, Patidar Rajesh, Chen Li, Wyczalkowski Matthew A, Jayasinghe Reyka G, Rodrigues Fernanda Martins, Terekhanova Nadezhda V, Li Yize, Lim Kian-Huat, Wang-Gillam Andrea, Van Tine Brian A, Ma Cynthia X, Aft Rebecca, Fuh Katherine C, Schwarz Julie K, Zevallos Jose P, Puram Sidharth V, Dipersio John F, Davis-Dusenbery Brandi, Ellis Matthew J, Lewis Michael T, Davies Michael A, Herlyn Meenhard, Fang Bingliang, Roth Jack A, Welm Alana L, Welm Bryan E, Meric-Bernstam Funda, Chen Feng, Fields Ryan C, Li Shunqiang, Govindan Ramaswamy, Doroshow James H, Moscow Jeffrey A, Evrard Yvonne A, Chuang Jeffrey H, Raphael Benjamin J, Ding Li
Abstract excerpt
Development of candidate cancer treatments is a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Toward this goal, we have established the genomic landscapes of 536 patient-derived xenograft (PDX) models across 25 cancer types, together with mutation, copy number, fusion, transcriptomic profiles, and NCI-MATCH arms. Compared with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.